Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Ghada F. Ahmed"'
Publikováno v:
Journal of Infection and Public Health, Vol 7, Iss 5, Pp 436-444 (2014)
Pseudomonas aeruginosa colonizes the lungs in cystic fibrosis (CF) and mechanically ventilated patients by binding to the cellular receptors on the surface of the lung epithelium. Studies have shown that blocking this interaction could be achieved wi
Externí odkaz:
https://doaj.org/article/8f7c95c678f44e049a64117d28b11720
Autor:
Anders Mellemgaard, Ghada F. Ahmed, Xiaoling Ou, Geoffrey R. Oxnard, Kiyotaka Yoh, Toyoaki Hida, Yuichiro Ohe, Hideo Saka, Manabu Hayama, Tomonori Hirashima, Ko Sugibayashi, Takayasu Kurata, Remy B. Verheijen
Publikováno v:
Targeted Oncology
Background Preliminary data suggest that combining savolitinib, a potent and highly selective MET-tyrosine kinase inhibitor (TKI), with osimertinib, a third-generation, irreversible, oral epidermal growth factor receptor-TKI (EGFR-TKI), may overcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6d759a02fad88de2c11b053077ec47c
https://doi.org/10.1007/s11523-021-00806-5
https://doi.org/10.1007/s11523-021-00806-5
Autor:
Yan Li, Torbjörn Vik, Dana Ghiorghiu, Corina Dota, Remy B. Verheijen, Stephen Walker, Ghada F. Ahmed, Tarjinder Sahota, Ronald Goldwater, Anders Mellemgaard, Weili Yan
Publikováno v:
Clinical Pharmacology in Drug Development. 10:521-534
Savolitinib (AZD6094, HMPL-504, volitinib) is an oral, bioavailable, selective MET-tyrosine kinase inhibitor. This randomized, double-blind, 3-way, crossover phase 1 study of savolitinib versus moxifloxacin (positive control) and placebo-evaluated ef
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cfa43b8d5c70c7e2da0232c94dd99868
https://doi.org/10.1002/cpdd.896
https://doi.org/10.1002/cpdd.896
Publikováno v:
The AAPS Journal. 23
Savolitinib is an oral, potent, and highly selective MET-tyrosine kinase inhibitor under investigation in various tumor types. A thorough QT study evaluated effects on QT interval after a 600-mg single savolitinib dose in healthy subjects. We report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82371156f681427747712f98c2b5a10a
https://doi.org/10.1208/s12248-021-00573-1
https://doi.org/10.1208/s12248-021-00573-1
Publikováno v:
The AAPS journal. 23(3)
Savolitinib is an oral, potent, and highly selective MET-tyrosine kinase inhibitor under investigation in various tumor types. A thorough QT study evaluated effects on QT interval after a 600-mg single savolitinib dose in healthy subjects. We report
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::97390e21db5b7c455ab11ed3ddc84f44
https://pubmed.ncbi.nlm.nih.gov/33733338
https://pubmed.ncbi.nlm.nih.gov/33733338
Autor:
Remy B. Verheijen, Yongqian Shu, Wei Li, Nong Yang, Caicun Zhou, Anders Mellemgaard, Coumaran Egile, Jian Fang, Ryan J. Hartmaier, Yi-Long Wu, Xiao-Qing Liu, Jianxing He, Liu Yang, Melanie M. Frigault, Jian-An Huang, Jianhua Chang, Shethah Morgan, Jin-Ji Yang, Gongyan Chen, Ghada F. Ahmed
Publikováno v:
Investigational new drugs. 39(2)
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are recommended first-line treatments in EGFR-mutated (EGFRm) non-small-cell lung cancer (NSCLC). However, acquired resistance (e.g. MET amplification) is frequently observed. Sa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8a9667ed8c5e43dee4052c24afcaa84
https://pubmed.ncbi.nlm.nih.gov/33052556
https://pubmed.ncbi.nlm.nih.gov/33052556
Autor:
Lillian Castriotta, Alwin Schuller, Ryan E. Henry, Evan Barry, Michelle DuPont, Maryann San Martin, Celina M. D'Cruz, Tarjinder Sahota, Ghada F. Ahmed, Rhys D.O. Jones, Mike Grondine, Alexandra Borodovsky, Klas Petersson, Rana Anjum
Publikováno v:
British journal of pharmacologyREFERENCES. 178(3)
Background and purpose Savolitinib (AZD6094, HMPL-504, volitinib) is an oral, potent, and highly MET receptor TK inhibitor. This series of studies aimed to develop a pharmacokinetic-pharmacodynamic (PK/PD) model to link inhibition of MET phosphorylat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1969ef65fbc2e2fa9a4f35c2c1a45da
https://pubmed.ncbi.nlm.nih.gov/33125717
https://pubmed.ncbi.nlm.nih.gov/33125717
Autor:
Xiaoqing Liu, Ryan J. Hartmaier, Caicun Zhou, Anders Mellemgaard, Jianhua Chang, Jian-An Huang, Remy B. Verheijen, Yongqian Shu, Jian Fang, Melanie M. Frigault, Jianxing He, Shethah Morgan, Yi-Long Wu, Gongyan Chen, Liu Yang, Jin-Ji Yang, Nong Yang, Coumaran Egile, Ghada F. Ahmed, Wei Li
Publikováno v:
SSRN Electronic Journal.
Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are recommended first-line treatments in EGFR- mutated non-small-cell lung cancer (NSCLC). However, acquired resistance (e.g. MET amplification) is common. Savolitini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0861615e691566f29183cccf00743af
https://doi.org/10.2139/ssrn.3514754
https://doi.org/10.2139/ssrn.3514754
Autor:
Rana Anjum, Andrew A. Mortlock, Klas Petersson, Stein Schalkwijk, Awlin Schuller, Rhys D.O. Jones, Areya Tabatabai, Ghada F. Ahmed
Publikováno v:
Cancer Research. 80:3017-3017
MET-amplification has been identified as a resistance mechanism in >5% of patients with non-small cell lung cancer (NSCLC) and 25% of those that progress on 1st/2nd or 3rd generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::301d33d6eb3a4c04ecc3ed7a8f9825ed
https://doi.org/10.1158/1538-7445.am2020-3017
https://doi.org/10.1158/1538-7445.am2020-3017
Autor:
Ghada F. Ahmed, Mireille Cantarini, Paul Frewer, Ryan J. Hartmaier, Jane Peters, Geoffrey R. Oxnard, M-J. Ahn, G. Hawkins, Tarjinder Sahota, Xiaocheng Li-Sucholeiki, P. Howarth
Publikováno v:
Journal of Thoracic Oncology. 14:S415-S416
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0d571b91f7f2fe5dd35761a12d946688
https://doi.org/10.1016/j.jtho.2019.08.849
https://doi.org/10.1016/j.jtho.2019.08.849